UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy

Annals of oncology, 2017-05, Vol.28 (5), p.958-968

2017

Volltextzugriff (PDF)

Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study

British journal of cancer, 2013-11, Vol.109 (12), p.3057-3066

2013

Volltextzugriff (PDF)

RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study

Annals of oncology, 2018-05, Vol.29 (5), p.1211-1219

2018

Volltextzugriff (PDF)

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

British journal of cancer, 2006-01, Vol.94 (2), p.259-267

2006

Volltextzugriff (PDF)

Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study

Annals of oncology, 2010-09, Vol.21 (9), p.1786-1793

2010

Volltextzugriff (PDF)

Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study

Annals of oncology, 2008-09, Vol.19 (9), p.1592-1599

2008

Volltextzugriff (PDF)

Conclusion et perspectives

Oncologie (Paris, France), 2017, Vol.19 (1-2), p.41-41

Bonnetain, F.

2017

Volltextzugriff (PDF)

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)

Annals of oncology, 2015-05, Vol.26 (5), p.873-879

2015

Volltextzugriff (PDF)

Malnutrition Is High and Underestimated During Chemotherapy in Gastrointestinal Cancer: An AGEO Prospective Cross-Sectional Multicenter Study

Nutrition and cancer, 2012-05, Vol.64 (4), p.535-542

2012

Volltextzugriff (PDF)

Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer

Gut, 2010-03, Vol.59 (3), p.341-347

2010

Volltextzugriff (PDF)

Time to deterioration in cancer randomized clinical trials for patient-reported outcomes data: a systematic review

Quality of life research, 2020-04, Vol.29 (4), p.867-878

2020

Volltextzugriff (PDF)

What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: Surrogacy in question?

European journal of cancer (1990), 2012-08, Vol.48 (12), p.1781-1790

2012

Volltextzugriff (PDF)

Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study

British journal of cancer, 2013-12, Vol.109 (12), p.3057-3066

2013

Volltextzugriff (PDF)

How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials

Annals of oncology, 2017-09, Vol.28 (9), p.2077-2085

2017

Volltextzugriff (PDF)

Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF

Annals of oncology, 2014-07, Vol.25 (7), p.1442-1447

2014

Volltextzugriff (PDF)

Endpoints in cancer clinical trials

Journal of visceral surgery, 2014-02, Vol.151 (1), p.17-22

2014

Volltextzugriff (PDF)

International validation of the EORTC QLQ-ELD14 questionnaire for assessment of health-related quality of life elderly patients with cancer

British journal of cancer, 2013-08, Vol.109 (4), p.852-858

2013

Volltextzugriff (PDF)

EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors

Annals of oncology, 2011-08, Vol.22 (8), p.1922-1926

2011

Volltextzugriff (PDF)

DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma

Annals of oncology, 2013-12, Vol.24 (12), p.3045-3050

2013

Volltextzugriff (PDF)

Cancer-related fatigue management: evaluation of a patient education program with a large-scale randomised controlled trial, the PEPs fatigue study

British journal of cancer, 2017-03, Vol.116 (7), p.849-858

2017

Volltextzugriff (PDF)

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)

Annals of oncology, 2015-12, Vol.26 (12), p.2505-2506

2015

Volltextzugriff (PDF)

Idarubicin‐loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial

Alimentary pharmacology & therapeutics, 2014-06, Vol.39 (11), p.1301-1313

2014

Volltextzugriff (PDF)

Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma

Annals of oncology, 2012-09, Vol.23 (9), p.2327-2335

2012

Volltextzugriff (PDF)

Impact of sentinel node biopsy on long-term quality of life in breast cancer patients

British journal of cancer, 2013-11, Vol.109 (11), p.2783-2791

2013

Volltextzugriff (PDF)

Health related quality of life and endpoints in oncology

Cancer radiothérapie, 2010-10, Vol.14 (6-7), p.515-518

Bonnetain, F

2010

Volltextzugriff (PDF)

1 – 25 von 341

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(326)
Mit Volltextzugriff
(315)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(94)
Humans
(93)
Life Sciences & Biomedicine
(92)
Female
(75)
Oncology
(74)
Middle Aged
(64)
Aged
(62)
Male
(58)
Adult
(45)
Quality Of Life
(43)
Life Sciences
(40)
Tumors
(40)
Cancer
(38)
Hematology, Oncology And Palliative Medicine
(38)
Biological And Medical Sciences
(35)
Medical Sciences
(35)
Treatment Outcome
(32)
Aged, 80 And Over
(25)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(20)
Disease-Free Survival
(19)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy

Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study

RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study

Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study

Conclusion et perspectives

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)

Malnutrition Is High and Underestimated During Chemotherapy in Gastrointestinal Cancer: An AGEO Prospective Cross-Sectional Multicenter Study

Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer

Time to deterioration in cancer randomized clinical trials for patient-reported outcomes data: a systematic review

What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: Surrogacy in question?

Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study

How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials

Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF

Endpoints in cancer clinical trials

International validation of the EORTC QLQ-ELD14 questionnaire for assessment of health-related quality of life elderly patients with cancer

EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors

DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma

Cancer-related fatigue management: evaluation of a patient education program with a large-scale randomised controlled trial, the PEPs fatigue study

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)

Idarubicin‐loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial

Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma

Impact of sentinel node biopsy on long-term quality of life in breast cancer patients

Health related quality of life and endpoints in oncology

Suchergebnisse filtern